https://orcid.org/0000-0002-2781-2178
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gyula Ostoros, Robert Hettle, Nefeli Georgoulia, Mehmet Berktas, Pratibha Chander, Ignacio Diaz Perez, Anne-Marie Couto, Christian Eichinger, Polly Field & Peter Morten. (2023) Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 23:12, pages 1305-1313.
Read now
Read now
Priyanka Gaitonde, Viktor Chirikov, Sneha Kelkar & Bengt Liljas. (2022) Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. Cancer Management and Research 14, pages 3421-3435.
Read now
Read now
Masaki Shiota, Raf De Moor, Yosuke Koroki, Dae Young Yu & David Bin-Chia Wu. (2022) Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan. Current Medical Research and Opinion 38:8, pages 1351-1359.
Read now
Read now
Articles from other publishers (7)
Myrto Lee, Hugo Larose, Martin Gräbeldinger, Jon Williams, Anne-Marie Baird, Susan Brown, Johannes Bruns, Russell Clark, Javier Cortes, Giuseppe Curigliano, Andrea Ferris, Louis P. Garrison, Y.K. Gupta, Ravindran Kanesvaran, Gary Lyman, Luca Pani, Zack Pemberton-Whiteley, Tomas Salmonson, Peter Sawicki, Barry Stein, Dong-Churl Suh, Galina Velikova & Jens Grueger. (2024) The evolving value assessment of cancer therapies: Results from a modified Delphi study. Health Policy OPEN 6, pages 100116.
Crossref
Crossref
Adel Shahnam, Udit Nindra, Jayesh Desai, Rina Hui, Marc Buyse, Ashley M Hopkins & Michael J Sorich. (2023) Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis. JNCI: Journal of the National Cancer Institute 115:12, pages 1475-1482.
Crossref
Crossref
Jamie Garside, Qin Shen, Bernd Westermayer, Michiel van de Ven, Sonja Kroep, Viktor Chirikov & Ingolf Juhasz-Böss. (2023) Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer. Clinical Therapeutics 45:10, pages 983-990.
Crossref
Crossref
Gabriella Chauca Strand, Naimi Johansson, Niklas Jakobsson, Carl Bonander & Mikael Svensson. (2023) Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?. Clinical Drug Investigation 43:8, pages 621-633.
Crossref
Crossref
Holly L. Cranmer, Gemma E. Shields & Ash Bullement. (2023) An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. Applied Health Economics and Health Policy 21:3, pages 385-394.
Crossref
Crossref
Eugena Stamuli, Sorcha Corry & Petter Foss. (2023) Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Crossref
Kexin Ling, Huli Qin, Yiman Feng, Hongxi Che, Jinxi Ding & Wei Li. (2022) Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China. Frontiers in Public Health 10.
Crossref
Crossref